To test the potential benefit of extending cognitive-behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking.Two-group parallel randomised controlled trial. Patients were randomized to receive non-extended CBT (n?=?111) or extended CBT (n?=?112) following a 26-week open-label treatment.Community clinic in the USA.219 smokers (mean age: 43?years; mean cigarettes/day: 18).All participants received 10?weeks of combined CBT?+?bupropion sustained release (bupropion SR)?+?nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion?+?nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10?weeks. Half of participants were randomized at 26?weeks to extended CBT (E-CBT) through week 48 and half to non-extended CBT (no additional CBT sessions).The primary outcome was expired CO-confirmed, seven-day point-prevalence (PP) at 52-week and 104-week follow-up. Analyses were based on intention-to-treat.PP-abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [OR 0.99; 95% CI (0.55,1.78)]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up [OR 0.79; 95% CI (0.44,1.40)].Prolonging cognitive-behavioral therapy from 26 to 48?weeks does not appear to improve long-term abstinence from smoking.
View details for DOI 10.1111/add.13806
View details for PubMedID 28239942